{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:56:19Z","timestamp":1768514179992,"version":"3.49.0"},"reference-count":51,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Three technologies are currently under active development for pathogen inactivation of red cell concentrates or whole blood (WB): the Intercept technology using S\u2010303 as an inactivating chemical; the Theraflex technology using UV\u2010C illumination; and the Mirasol technology using riboflavin and UV light. For the UV\u2010C technology, no in vivo data are available. For the other two technologies, recovery, survival and life span of the treated red blood cells (RBCs) are shortened but are within objective requirements, including a 24\u2010h recovery &gt;75%. S\u2010303\u2010treated RBCs were transfused in various patient groups and, so far, showed no relevant differences in the clinical endpoints. In early studies, S\u2010303\u2010reactive antibodies were observed, which prompted changes in the inactivation process, and no further antibody formation was seen. The one published study with the riboflavin\/UV procedure showed good effectiveness of treated WB, with haemoglobin increment similar to that of untreated WB. When considering potential implementation of pathogen inactivation strategies, a balance should be struck between microbiological safety, component quality and cost. None of the current technologies is in a stage for large\u2010scale blood bank application, either because of limited availability of evidence of satisfactory in vitro quality data or because of the ongoing requirement of clinical trials in a broad spectrum of patients.<\/jats:p>","DOI":"10.1111\/vox.70132","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:12:03Z","timestamp":1761721923000},"page":"17-25","source":"Crossref","is-referenced-by-count":1,"title":["Pathogen inactivation of red cell concentrates and whole blood:\n                    <scp>II<\/scp>\n                    . In vivo human recovery studies, clinical trials and future directions"],"prefix":"10.1111","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2093-3604","authenticated-orcid":false,"given":"Pieter F.","family":"van der Meer","sequence":"first","affiliation":[{"name":"Department of Product and Process Development Sanquin Blood Bank  Amsterdam The Netherlands"},{"name":"Department of Haematology Haga Teaching Hospital  The Hague The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-7233","authenticated-orcid":false,"given":"Jose A.","family":"Cancelas","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute, Harvard Medical School  Boston Massachusetts USA"},{"name":"Hoxworth Blood Center, University of Cincinnati  Cincinnati Ohio USA"},{"name":"Division of Experimental Hematology, Cancer and Blood Diseases Institute, Department of Pediatrics Cincinnati Children's Hospital Medical Center  Cincinnati Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2864-4073","authenticated-orcid":false,"given":"Thomas R. L.","family":"Klei","sequence":"additional","affiliation":[{"name":"Department of Product and Process Development Sanquin Blood Bank  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01642.x"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02669.x"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00973.x"},{"key":"e_1_2_12_5_1","first-page":"8","article-title":"A randomized, controlled, 2\u2010period crossover study of recovery and lifespan of radiolabeled autologous 35\u2010day\u2010old red blood cells prepared with a modified S\u2010303 treatment for pathogen inactivation","volume":"95","author":"Cancelas JA","year":"2008","journal-title":"Vox Sang"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03163.x"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12500"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03027.x"},{"key":"e_1_2_12_9_1","unstructured":"Clinical Experiences Knowledge Database.Trial NCT00742001. Available from:https:\/\/cdek.pharmacy.purdue.edu\/trial\/NCT00742001\/. Last accessed 31 Jul 2024."},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14084"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16500"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00583.x"},{"key":"e_1_2_12_13_1","first-page":"121","article-title":"S\u2010303 pathogen inactivated red blood cells in patients with hemoglobinopaties participating in chronic transfusion programs: preliminary safety and efficacy results","volume":"89","author":"Conlan MGC","year":"2005","journal-title":"Vox Sang"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15965"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14528"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15963"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12757"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07831-x"},{"key":"e_1_2_12_19_1","unstructured":"Available from:https:\/\/ir.cerus.com\/press\u2010releases\/press\u2010releases\u2010details\/2024\/Cerus\u2010Corporation\u2010Announces\u2010Positive\u2010Topline\u2010Results\u2010for\u2010the\u2010Phase\u20103\u2010Clinical\u2010Trial\u2010of\u2010the\u2010INTERCEPT\u2010Blood\u2010System\u2010for\u2010Red\u2010Blood\u2010Cells\u2010in\u2010Cardiovascular\u2010Surgery\u2010Patients\/default.aspx. Last accessed 7 Aug 2024."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00581-X"},{"key":"e_1_2_12_21_1","unstructured":"Available from:https:\/\/clinicaltrials.gov\/study\/NCT03329404. Last accessed 31 Jul 2024."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06137-8"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13259"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01423.x"},{"key":"e_1_2_12_25_1","unstructured":"Available from:https:\/\/professionaleducation.blood.ca\/en\/transfusion\/publications\/faq\u2010canadian\u2010blood\u2010services\u2010platelet\u2010bacterial\u2010screening. Last accessed 31 Jul 2024."},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/vox.70132","article-title":"Pathogen inactivation of red cell concentrates and whole blood. I. History, technologies, and in vitro studies","volume":"121","author":"Van der Meer PF","year":"2026","journal-title":"Vox Sang"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12895"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13959"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000495257"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15766"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2003.00358.x"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13280"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40140-021-00514-w"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15426"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12910"},{"key":"e_1_2_12_36_1","unstructured":"World Health Organization.Blood safety and availability. Available from:https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blood-safety-and-availability. Last accessed 31 Jul 2024."},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2008.05.003"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00021.x"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-2824.2006.00035.x"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90931-2"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15791"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13993"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2000.0099"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16979"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12224"},{"key":"e_1_2_12_46_1","first-page":"434","article-title":"Preservation of red blood cells with purines and nucleosides. III. Synthesis of adenine, guanine, and hypoxanthine nucleotides","volume":"107","author":"Strauss D","year":"1980","journal-title":"Folia Haematol Int Mag Klin Morphol Blutforsch"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1975.tb00484.x"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12779"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15485"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12988"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14949"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14497"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.70132","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:07:28Z","timestamp":1768435648000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/vox.70132"],"URL":"https:\/\/doi.org\/10.1111\/vox.70132","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}